Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

The Unidad de Oncologia Toracica at Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. is strongly focused on respiratory tract diseases and neoplasms, especially non-small cell lung cancer, small cell lung cancer, and ALK-positive or EGFR-mutated lung tumors. These trials are mainly designed to improve treatment effectiveness, test new targeted and immune-based therapies, and refine care after surgery or chemoradiotherapy.

• Locally advanced, metastatic, and resectable non-small cell lung cancer
• Small cell lung cancer and relapsed disease
• Molecularly selected lung tumors with ALK, EGFR exon 20 insertion, or KRAS G12C alterations
• Perioperative and maintenance strategies to improve outcomes in lung cancer

Across multiple studies, the site is helping evaluate whether newer combinations can extend survival, reduce recurrence, and better control advanced thoracic cancers.

Research in breast cancer is a major activity at this site, spanning hormonal diseases and neoplasms. The trials include ER-positive/HER2-negative disease, triple negative breast cancer, and advanced or metastatic settings, with the aim of improving endocrine therapy, testing targeted treatments, and strengthening disease control before and after standard care.

• ER-positive/HER2-negative early and advanced breast cancer
• Triple negative breast cancer
• Advanced or metastatic breast cancer with molecular markers such as ESR1 and PIK3CA
• Studies of treatment response, recurrence prevention, and maintenance therapy

These studies reflect a broad effort to personalize treatment and improve long-term outcomes for patients with hormone-sensitive and aggressive breast cancers.

The site conducts extensive research in hemic and lymphatic diseases, with a strong emphasis on acute myeloid leukemia, myelodysplastic syndrome, lymphomas, and multiple myeloma. Many trials are aimed at testing new drug combinations, improving response in relapsed or hard-to-treat disease, and supporting better disease control for patients with limited options.

• Acute myeloid leukemia and related high-risk subtypes
• Myelodysplastic syndrome and overlap disorders
• Follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma
• Multiple myeloma and other advanced blood cancers

At IRST Meldola, these investigations are helping advance both frontline and relapse-focused treatment strategies in hematologic cancer care.

Clinical trials in skin and connective tissue diseases focus on melanoma and other high-risk solid tumors, including resected and unresectable disease. The main purpose is to evaluate newer immunotherapy-based approaches, improve recurrence prevention, and strengthen treatment options for patients with advanced disease.

• Resected high-risk melanoma
• Unresectable or metastatic melanoma
• Studies of adjuvant and first-line treatment approaches
• Research aimed at reducing relapse and extending survival

This area shows the site’s active role in testing approaches that may improve both early post-surgery protection and treatment for advanced melanoma.

Work in digestive system diseases includes studies in esophageal carcinoma, gastroesophageal adenocarcinoma, colorectal cancer, biliary tract cancers, and gastrointestinal stromal tumor. These trials are focused on improving surgical outcomes, testing targeted treatments, and evaluating whether newer therapies can better control advanced gastrointestinal cancers.

• Esophageal and gastroesophageal cancers
• Colorectal cancer with molecular selection
• Biliary tract cancers
• Gastrointestinal stromal tumor

The research portfolio reflects a broad effort to improve both curative-intent and advanced-disease treatment strategies across GI oncology.

Several trials address uncommon cancers within neoplasms, including retroperitoneal sarcoma, leiomyosarcoma, liposarcoma, and selected neuroendocrine tumors. The goal is to determine whether preoperative or targeted treatment can improve surgical results, disease control, and long-term outcomes in cancers where effective options are often limited.

• High-risk retroperitoneal sarcoma
• Leiomyosarcoma and liposarcoma
• Neuroendocrine tumors of the lung and thymus
• Studies supporting surgery, targeted therapy, and disease-free survival

These investigations highlight the site’s interest in rare and complex tumors that require highly specialized oncology expertise.

Beyond treatment studies, the site is also active in diagnosis and analytical, diagnostic and therapeutic techniques and equipment. Trials here examine advanced imaging and biomarker-guided approaches to improve tumor detection, staging, and treatment selection across multiple cancer types.

• PET/CT imaging for better tumor detection
• Studies comparing diagnostic performance in lymphoma and solid tumors
• Research supporting more accurate staging and response assessment
• Biomarker-driven selection of patients for targeted therapy

These studies help connect early diagnosis with more personalized cancer care, supporting both clinical decisions and future treatment planning.

The trial portfolio also covers a wide range of immune system diseases, hormonal diseases, and additional advanced cancers, reflecting the breadth of oncology research at this hospital-based center in Meldola. Many studies are designed to test new combinations, improve maintenance treatment, and evaluate whether novel therapies can extend survival or delay progression in difficult-to-treat disease.

• Advanced solid tumors with specific molecular features
• Ovarian, prostate, and renal cancer studies
• Maintenance and relapse-prevention strategies
• Immune-based and targeted treatment evaluation

With 58 trials and 61 investigators, IRST Romagna supports a diverse research environment that brings together precision oncology, surgery-related studies, and treatment innovation.